JP2005504101A5 - - Google Patents

Download PDF

Info

Publication number
JP2005504101A5
JP2005504101A5 JP2003530847A JP2003530847A JP2005504101A5 JP 2005504101 A5 JP2005504101 A5 JP 2005504101A5 JP 2003530847 A JP2003530847 A JP 2003530847A JP 2003530847 A JP2003530847 A JP 2003530847A JP 2005504101 A5 JP2005504101 A5 JP 2005504101A5
Authority
JP
Japan
Prior art keywords
amino
triazole
anilino
pharmaceutical composition
phenylaminothiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003530847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005504101A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/030059 external-priority patent/WO2003027275A1/en
Publication of JP2005504101A publication Critical patent/JP2005504101A/ja
Publication of JP2005504101A5 publication Critical patent/JP2005504101A5/ja
Pending legal-status Critical Current

Links

JP2003530847A 2001-09-27 2002-09-23 緑内障を治療するためのグリコゲンシンターゼキナーゼ−3(gsk−3)インヒビター Pending JP2005504101A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32539001P 2001-09-27 2001-09-27
PCT/US2002/030059 WO2003027275A1 (en) 2001-09-27 2002-09-23 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005211956A Division JP2005320350A (ja) 2001-09-27 2005-07-21 緑内障を治療するためのグリコゲンシンターゼキナーゼ−3(gsk−3)インヒビター

Publications (2)

Publication Number Publication Date
JP2005504101A JP2005504101A (ja) 2005-02-10
JP2005504101A5 true JP2005504101A5 (enExample) 2006-01-05

Family

ID=23267686

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003530847A Pending JP2005504101A (ja) 2001-09-27 2002-09-23 緑内障を治療するためのグリコゲンシンターゼキナーゼ−3(gsk−3)インヒビター
JP2005211956A Pending JP2005320350A (ja) 2001-09-27 2005-07-21 緑内障を治療するためのグリコゲンシンターゼキナーゼ−3(gsk−3)インヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005211956A Pending JP2005320350A (ja) 2001-09-27 2005-07-21 緑内障を治療するためのグリコゲンシンターゼキナーゼ−3(gsk−3)インヒビター

Country Status (15)

Country Link
US (2) US7598288B2 (enExample)
EP (2) EP1430120A4 (enExample)
JP (2) JP2005504101A (enExample)
KR (1) KR20040047824A (enExample)
CN (2) CN1561393A (enExample)
AR (1) AR036684A1 (enExample)
AU (1) AU2002334635B2 (enExample)
BR (1) BR0212924A (enExample)
CA (1) CA2460000C (enExample)
MX (1) MXPA04002137A (enExample)
PL (1) PL207022B1 (enExample)
RU (1) RU2297243C2 (enExample)
TW (2) TWI335221B (enExample)
WO (1) WO2003027275A1 (enExample)
ZA (1) ZA200401846B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2400543C (en) * 2001-08-31 2011-11-01 Centre For Addiction And Mental Health The involvement of the bdnf gene in mood disorders
US7351407B2 (en) * 2002-04-30 2008-04-01 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
EP1616568A3 (en) * 2002-04-30 2006-06-21 Alcon, Inc GSK-3 inhibitors and CDK inhibitors as anti-glaucoma agents
US7385055B2 (en) 2003-05-19 2008-06-10 Board Of Trustees Of Michigan State University Preparation of hymenialdisine derivatives and use thereof
MXPA06006862A (es) * 2003-12-22 2007-01-26 Alcon Inc Agentes para el tratamiento de la retinopatia diabetica y formacion de drusen en degeneracion macular.
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
DE602004005617T2 (de) * 2003-12-22 2007-12-13 Alcon Inc. Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
JP2007516989A (ja) * 2003-12-24 2007-06-28 バイエル クロップサイエンス ゲーエムベーハー 植物成長調節
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
BRPI0510954A (pt) * 2004-05-12 2007-11-20 Bayer Cropscience Gmbh regulação do crescimento de uma planta
WO2006089874A1 (en) * 2005-02-22 2006-08-31 Gpc Biotech Ag Benzo[2,3]azepino[4,5-b]indol-6-ones
JP2008533050A (ja) 2005-03-11 2008-08-21 アルコン,インコーポレイテッド 緑内障を処置するためのフリッツルド関連蛋白質―1のrnai媒介性阻害
RU2284192C1 (ru) * 2005-04-01 2006-09-27 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения РФ Способ лечения глаукомной оптической нейропатии
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
EP1757607A1 (en) 2005-08-24 2007-02-28 Molisa GmbH N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases
US7884119B2 (en) 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
AU2007258527A1 (en) * 2006-06-12 2007-12-21 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
EP2114954B1 (en) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
JP2010514810A (ja) 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ, インコーポレイテッド Axlインヒビターとして有用な置換トリアゾール
AU2007342005A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
ES2404668T3 (es) 2006-12-29 2013-05-28 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con arilo bicíclico puenteado y heteroarilo bicíclico puenteado, útiles como agentes inhibidores del axl
PT2078010E (pt) 2006-12-29 2014-05-07 Rigel Pharmaceuticals Inc Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl
CA2704052C (en) 2007-10-26 2015-04-21 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ, インコーポレイテッド Axl阻害剤として有用な多環式ヘテロアリール置換トリアゾール
US8431594B2 (en) 2008-07-09 2013-04-30 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors
RU2555326C2 (ru) 2009-01-16 2015-07-10 Риджел Фармасьютикалз, Инк. ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
RU2456266C1 (ru) * 2011-04-06 2012-07-20 Максим Эдуардович Запольский Производные 4,4'-бифениламидов, обладающие фармакологической активностью, и лекарственные средства на их основе
WO2014140896A2 (es) 2013-03-15 2014-09-18 Fundacio Privada Institut De Recerca Biomedica Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US11666777B2 (en) 2014-05-12 2023-06-06 Gholam A. Peyman Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient
US12396889B2 (en) 2014-05-12 2025-08-26 Gholam A. Peyman Lamellar corneal autologous or homologous graft in refractive surgery
US10925889B2 (en) 2014-05-12 2021-02-23 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US10881503B2 (en) 2014-05-12 2021-01-05 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US11338059B2 (en) 2014-05-12 2022-05-24 Gholam A. Peyman Method of corneal and scleral inlay crosslinking and preservation
US10583221B2 (en) 2014-05-12 2020-03-10 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US11648261B2 (en) 2014-05-12 2023-05-16 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US11565023B2 (en) 2014-05-12 2023-01-31 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US11045352B2 (en) 2014-05-12 2021-06-29 Gholam A. Peyman Methods for treatment of dry eye and other acute or chronic inflammatory processes
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
WO2019221959A1 (en) * 2018-05-16 2019-11-21 Peyman Gholam A Method of treating, reducing, or alleviating a medical condition in a patient
US12226478B2 (en) 2019-04-28 2025-02-18 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US11707518B2 (en) 2019-04-28 2023-07-25 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US12110278B2 (en) * 2020-10-13 2024-10-08 Yale University Selective JAK2 pseudokinase ligands and methods of use

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK75289A3 (en) 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
IL94274A0 (en) 1989-05-05 1991-03-10 Goedecke Ag Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
DE3914764A1 (de) 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
SK108293A3 (en) 1991-04-11 1994-09-07 Schering Corp Anti-tumor and anti-psoriatic agents
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
CA2130836A1 (en) 1992-03-20 1993-09-30 Martin J. Slater Further indole derivatives with antiviral activity
AU3761393A (en) 1992-03-20 1993-10-21 Wellcome Foundation Limited, The Indole derivatives with antiviral activity
DE4217964A1 (de) 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
DE4243321A1 (de) 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
GB9319297D0 (en) 1993-09-17 1993-11-03 Wellcome Found Indole derivatives
GB9416467D0 (en) 1994-08-13 1994-10-05 Wellcome Found Compounds for use in medicine
US5681854A (en) 1995-11-22 1997-10-28 Alcon Laboratories, Inc. Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
WO1997041854A1 (en) 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
PE91698A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91498A1 (es) 1996-07-29 1998-12-22 Hoffmann La Roche Pirroles sustituidos
SE9603283D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
SE9603285D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
AU735127B2 (en) 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
WO1999042100A1 (en) 1998-02-23 1999-08-26 Sagami Chemical Research Center Cell death inhibitors
ES2194468T3 (es) * 1998-05-29 2003-11-16 Centre Nat Rech Scient Uso de derivados del bisindol indigoide para la fabricacion de un medicamento para inhibir quinasas dependientes de ciclinas.
JP2002527419A (ja) 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Gsk−3阻害物質としてのピロール−2,5−ジオン類
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
GB9918180D0 (en) 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions
EP1224932A4 (en) * 1999-08-20 2002-10-16 Sagami Chem Res ACTIVE SUBSTANCES TO INHIBIT CELL DEATH
FR2801216A1 (fr) 1999-11-23 2001-05-25 Centre Nat Rech Scient Utilisation de derives d'indirubine pour la fabrication de medicaments
ES2213996T3 (es) 1999-12-08 2004-09-01 Centre National De La Recherche Scientifique (Cnrs) Uso de himenialdisina o sus derivados en la fabricacion de medicamentos.
EP1244461A2 (en) 1999-12-23 2002-10-02 The Ontario Cancer Institute INHIBITION OF GSK-3$g(b)
WO2001049709A1 (en) 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
WO2001056567A1 (en) 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
CA2401775A1 (en) 2000-02-29 2001-09-07 Abbot F. Clark Diagnostics and therapeutics for glaucoma
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
WO2001070727A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
EP1136099A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors
NZ547205A (en) 2001-09-21 2007-11-30 Sanofi Aventis Intermediates of substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives

Similar Documents

Publication Publication Date Title
RU2004112766A (ru) Ингибиторы киназы-3 гликогенсинтазы (gsk-3) для лечения глаукомы
RU2485114C2 (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
RU2489426C2 (ru) Производные аминопиразола
RU2386620C2 (ru) Производные пиридазин-3(2н)-она и их применение в качестве ингибиторов фдэ4
JP2019077725A5 (enExample)
JP2007521264A (ja) 新規用途i
RU2005135562A (ru) Производные пиразола в качестве ингибиторов фосфодиэстеразы 4
RU2011116232A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
JP2007505091A5 (enExample)
JP2004520292A5 (enExample)
RU2008141509A (ru) Mglur5 модуляторы 1
RU2003118448A (ru) Производные замещенного триазолдиамина и их применение в качестве ингибиторов киназы
HRP20150082T1 (hr) Derivati pirazolo piridina kao inhibitori nadph oksidaze
JP2007516173A5 (enExample)
RU2001121186A (ru) Производные пиразолкарбоновой кислоты, их получение, содержащие их фармацевтические композиции
HRP20130143T1 (hr) Derivati pirazolo piridina kao inhibitori nadph oksidaze
JP2011510929A5 (enExample)
RU2006146608A (ru) ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ
JP2003510359A5 (enExample)
JP2005532371A5 (enExample)
RU2011116226A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
JP2011527675A5 (enExample)
JP2006524686A5 (enExample)
RU2332996C2 (ru) Производные гидразонпиразола и их применение в качестве лекарственного средства
JP2022552158A5 (enExample)